Skip to content
DataLookout
Menu

NCT05015439

Cannabidiol (CBD) in Adults With ASD

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 15 versions: 14 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Dec 2026 to Dec 2027
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 10 of 10 entries
    • Collaborators: details revised at 1 of 1 entry
  2. Notable Primary and study completion dates pushed to Dec 2026v14
  3. Notable Primary completion date: Nov 2024 to Nov 2025
    • Study completion date: Dec 2024 to Dec 2025
    • Collaborator revised
    v13
  4. Notable Primary completion date: Dec 2023 to Nov 2024
    • Study completion date: Mar 2024 to Dec 2024
    v11
  5. Minor Start date changed from estimate of Apr 2023 to Apr 20, 2023v10
Show 8 earlier versionsHide 8 earlier versions
  1. Notable Start date: Dec 2022 to Apr 2023v9
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date: Nov 2022 to Dec 2022
    v8
  3. Minor Start date: Oct 2022 to Nov 2022v7
  4. Minor Primary completion date: Nov 2023 to Dec 2023
    • Study completion date: Feb 2024 to Mar 2024
    • Start date: Sep 2022 to Oct 2022
    v6
  5. Notable Start date: Jun 2022 to Sep 2022
    • Primary completion date: Aug 2023 to Nov 2023
    • Study completion date: Nov 2023 to Feb 2024
    v5
  6. Notable Start date: Mar 2022 to Jun 2022
    • Primary completion date: May 2023 to Aug 2023
    • Study completion date: Aug 2023 to Nov 2023
    v4
  7. Notable Start date: Dec 2021 to Mar 2022v3
  8. Notable Start date: Sep 2021 to Dec 2021
    • Primary completion date: Feb 2023 to May 2023
    • Study completion date: May 2023 to Aug 2023
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in Aberrant Behaviors as assessed by the Aberrant Behavior Checklist
Timeframe: baseline and six weeks

Secondary (10)

Change in Anxiety as assessed by the Hamilton Anxiety Rating Scale
Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
Change in Clinical Global Impression Scale-Improvement (CGI)
Change in neuropsychiatric symptomatology as assessed by the Neuropsychiatric Inventory Questionnaire (NPI-Q)
Change in Waisman Activities of Daily Living scale
Show 5 moreShow less
Change in Social Communication Questionnaire
Change in Mini Mental State Examination (MMSE)
Change in Adverse Effects- Drug Effect Questionnaire (DEQ) Subjective
Change in Adverse Effects- Drug Effect Questionnaire (DEQ) Informant
Change in Adverse Effects- Medication Side-Effects Questionnaire

Arms and interventions

CannabidiolExperimental

Participants will receive cannabidiol, starting at 100 mg twice daily, and increased to 200 mg twice daily by week 3. This arm will last six weeks.

PlaceboPlacebo comparator

Participants will receive six weeks of placebo.

Drugs: Cannabidiol, Placebo

Sites

1 site in 1 country

  • JHBMCBaltimore, Maryland, United States